You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

https://doi.org/10.1136/lupus-2018-000286corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Science, Medicine 2018;5:e000286. doi: 10.1136/lupus-2018-000286

    This article has been corrected since it first published. This is to inform that co-author Wendy I White’s affiliation was addressed incorrectly. Her correct affiliation is: Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA.

    Below is the updated information on the authors’ affiliation.

    Kerry A Casey,1 Xiang Guo,2 Michael A Smith,1 Shiliang Wang,2 Dominic Sinibaldi,3 Miguel A Sanjuan,1 Liangwei Wang,4 Gabor G Illei,5 Wendy I White2

    1Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, Maryland, USA

    2Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA

    3Research Bioinformatics, MedImmune LLC, Gaithersburg, Maryland, USA

    4Biostatistics, MedImmune LLC, Gaithersburg, Maryland, USA

    5Clinical Development, MedImmune LLC, Gaithersburg, Maryland, USA